Immutep Limited (IMM.AX)
AUD 0.23
(-6.12%)
AUD 0.23
(-6.12%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | -122.18 Million AUD | -56.13% |
| 2021 | -78.26 Million AUD | -36.55% |
| 2020 | -57.31 Million AUD | -231.85% |
| 2019 | -17.27 Million AUD | -93.5% |
| 2018 | -8.92 Million AUD | 46.97% |
| 2017 | -16.82 Million AUD | -160.6% |
| 2016 | -6.45 Million AUD | 59.26% |
| 2015 | -15.85 Million AUD | -201.88% |
| 2014 | -5.25 Million AUD | 63.02% |
| 2013 | -14.2 Million AUD | 35.52% |
| 2012 | -22.02 Million AUD | -29.51% |
| 2011 | -17 Million AUD | 62.98% |
| 2010 | -45.93 Million AUD | -207.42% |
| 2009 | -14.94 Million AUD | -2003.79% |
| 2008 | -710.17 Thousand AUD | 35.98% |
| 2007 | -1.1 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 Q2 | -67.42 Million AUD | 0.0% |
| 2022 Q4 | -122.18 Million AUD | 0.0% |
| 2022 FY | -122.18 Million AUD | -56.13% |
| 2021 Q4 | -78.26 Million AUD | 0.0% |
| 2021 FY | -78.26 Million AUD | -36.55% |
| 2021 Q2 | -96.61 Million AUD | 0.0% |
| 2020 Q4 | -57.31 Million AUD | 0.0% |
| 2020 Q2 | -45.12 Million AUD | 0.0% |
| 2020 FY | -57.31 Million AUD | -231.85% |
| 2019 Q2 | -12.03 Million AUD | 0.0% |
| 2019 Q4 | -17.27 Million AUD | 0.0% |
| 2019 FY | -17.27 Million AUD | -93.5% |
| 2018 Q2 | -18.85 Million AUD | 0.0% |
| 2018 Q4 | -8.92 Million AUD | 0.0% |
| 2018 FY | -8.92 Million AUD | 46.97% |
| 2017 Q2 | -7.49 Million AUD | 0.0% |
| 2017 FY | -16.82 Million AUD | -160.6% |
| 2017 Q4 | -16.82 Million AUD | 0.0% |
| 2016 Q2 | -11.16 Million AUD | 0.0% |
| 2016 Q3 | -8.28 Million AUD | 25.78% |
| 2016 FY | -6.45 Million AUD | 59.26% |
| 2016 Q4 | -6.45 Million AUD | 22.09% |
| 2015 Q2 | -20.78 Million AUD | 0.0% |
| 2015 Q4 | -15.85 Million AUD | 0.0% |
| 2015 FY | -15.85 Million AUD | -201.88% |
| 2014 Q2 | -5.06 Million AUD | 0.0% |
| 2014 Q4 | -5.25 Million AUD | 0.0% |
| 2014 FY | -5.25 Million AUD | 63.02% |
| 2013 FY | -14.2 Million AUD | 35.52% |
| 2013 Q2 | -17.26 Million AUD | 0.0% |
| 2013 Q4 | -14.2 Million AUD | 0.0% |
| 2012 Q2 | -11.02 Million AUD | 0.0% |
| 2012 FY | -22.02 Million AUD | -29.51% |
| 2012 Q4 | -22.02 Million AUD | 0.0% |
| 2011 FY | -17 Million AUD | 62.98% |
| 2011 Q4 | -17 Million AUD | 0.0% |
| 2010 FY | -45.93 Million AUD | -207.42% |
| 2009 FY | -14.94 Million AUD | -2003.79% |
| 2008 FY | -710.17 Thousand AUD | 35.98% |
| 2007 FY | -1.1 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -14357.33% |
| Acrux Limited | -1.45 Million AUD | -8280.621% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | -54.069% |
| BTC Health Limited | -2.02 Million AUD | -5942.536% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -3902.273% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 10.488% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 33.226% |
| Biome Australia Limited | -1.56 Million AUD | -7718.588% |
| Hexima Limited | -2.22 Million AUD | -5388.666% |
| Memphasys Limited | 4.13 Million AUD | 3054.739% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | -614.809% |
| Noxopharm Limited | -2.31 Million AUD | -5166.952% |
| Prescient Therapeutics Limited | -10.16 Million AUD | -1102.333% |
| Race Oncology Limited | -17.18 Million AUD | -610.866% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | -557.815% |
| Starpharma Holdings Limited | -19.83 Million AUD | -516.123% |
| Tissue Repair Ltd | -16.44 Million AUD | -643.197% |
| Biotron Limited | -386.06 Thousand AUD | -31549.722% |
| Alterity Therapeutics Limited | -12.47 Million AUD | -879.095% |
| CSL Limited | 15.76 Billion AUD | 100.775% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | -546.548% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -12341.562% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -17120.502% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 2511.318% |
| Patrys Limited | -2.24 Million AUD | -5353.277% |
| Orthocell Limited | -19.92 Million AUD | -513.255% |
| Imugene Limited | -91.56 Million AUD | -33.452% |
| PYC Therapeutics Limited | -65.76 Million AUD | -85.806% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -1832.201% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -1869.077% |
| Arovella Therapeutics Limited | -12.71 Million AUD | -861.031% |
| Nanollose Limited | -96.22 Thousand AUD | -126883.058% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -1928.018% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -2366.41% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -6600.485% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -9766.647% |
| Nyrada Inc. | -4.76 Million AUD | -2461.96% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | -15.5% |
| Dimerix Limited | -21.99 Million AUD | -455.614% |
| PharmAust Limited | -9.71 Million AUD | -1157.855% |
| AnteoTech Limited | -5 Million AUD | -2343.044% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | -594.989% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -3497.898% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -2192.81% |
| Actinogen Medical Limited | -9.13 Million AUD | -1238.085% |
| Immuron Limited | -11.48 Million AUD | -964.014% |
| Argenica Therapeutics Limited | -15.91 Million AUD | -667.876% |